Published in Thorax on May 01, 2005
Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) (2008) 1.86
An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.73
Impact of nutritional status on body functioning in chronic obstructive pulmonary disease and how to intervene. Curr Opin Clin Nutr Metab Care (2008) 0.90
Plasma polyunsaturated fatty acids and age-related physical performance decline. Rejuvenation Res (2009) 0.85
Nutrition and respiratory health--feature review. Nutrients (2015) 0.84
Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review. ERJ Open Res (2016) 0.81
Fish intake and risk of chronic obstructive pulmonary disease in 2 large US cohorts. Am J Clin Nutr (2014) 0.79
Undernutrition in patients with COPD and its treatment. Nutrients (2013) 0.78
Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress. FEBS Open Bio (2012) 0.77
Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults. Physiol Rep (2016) 0.77
Relationship between nutritional risk and exercise capacity in severe chronic obstructive pulmonary disease in male patients. Int J Chron Obstruct Pulmon Dis (2015) 0.75
The Toxicological Mechanisms of Environmental Soot (Black Carbon) and Carbon Black: Focus on Oxidative Stress and Inflammatory Pathways. Front Immunol (2017) 0.75
IGF-1 Attenuates Hypoxia-Induced Atrophy but Inhibits Myoglobin Expression in C2C12 Skeletal Muscle Myotubes. Int J Mol Sci (2017) 0.75
Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis (1969) 6.00
Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A (1993) 4.56
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A (1994) 3.00
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta (1996) 2.83
Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1994) 2.06
Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med (2003) 2.04
Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med (1995) 1.98
Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med (1996) 1.67
Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1996) 1.63
Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition (2003) 1.60
Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J (2002) 1.55
Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer (2004) 1.51
The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer (1999) 1.46
Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. N Engl J Med (1994) 1.36
Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J (2002) 1.33
Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.33
Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax (2000) 1.33
Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J (1997) 1.26
Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med (1995) 1.25
Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) (1997) 1.15
NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax (2004) 1.14
Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest (2003) 1.12
The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr (2002) 1.10
Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 1.07
Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. Free Radic Biol Med (2003) 1.04
Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.04
Influence of age and stature on exercise capacity during incremental cycle ergometry in men and women. Am Rev Respir Dis (1989) 1.02
Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.01
Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ (2005) 0.98
Controversies in epidemiology of occupational asthma. Eur Respir J (2003) 0.96
Decreased mechanical efficiency in clinically stable patients with COPD. Thorax (1997) 0.94
Long-term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. Respir Med (1995) 0.85
Exercise-induced hypoxaemia in master athletes: effects of a polyunsaturated fatty acid diet. Eur J Appl Physiol Occup Physiol (1995) 0.77
A dynamic population model of disease progression in COPD. Eur Respir J (2005) 2.59
Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J (2010) 2.50
Obesity and the lung: 5. Obesity and COPD. Thorax (2008) 2.22
Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax (2005) 2.03
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 1.94
Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax (2007) 1.94
A novel technique for nonvolitional assessment of quadriceps muscle endurance in humans. J Appl Physiol (1985) (2007) 1.80
The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J (2009) 1.71
Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract (2002) 1.66
The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr (2002) 1.64
Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration (2012) 1.54
Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J (2009) 1.48
Whole-body resting and exercise-induced lipolysis in sarcopenic [corrected] patients with COPD. Eur Respir J (2008) 1.43
Are patients with COPD psychologically distressed? Eur Respir J (2005) 1.35
Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J (2002) 1.33
Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med (2008) 1.27
PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab (2009) 1.22
Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.22
The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J (2006) 1.18
Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. Clin Exp Allergy (2007) 1.17
Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med (2006) 1.16
ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med (2003) 1.15
Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med (2005) 1.13
Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol (2009) 1.13
Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J (2007) 1.13
Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. Fam Pract (2005) 1.12
Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax (2005) 1.09
A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med (2009) 1.08
Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun (2002) 1.07
Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J (2003) 1.01
TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J (2010) 1.01
Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.01
Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3β. Cell Mol Life Sci (2010) 0.99
The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985) (2012) 0.99
Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax (2008) 0.97
Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol (2013) 0.97
ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. Clin Nutr (2006) 0.96
Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy (2009) 0.96
Candidate genes for COPD in two large data sets. Eur Respir J (2010) 0.96
Leptin as local inflammatory marker in COPD. Respir Med (2005) 0.91
Enhanced anabolic response to milk protein sip feeding in elderly subjects with COPD is associated with a reduced splanchnic extraction of multiple amino acids. Clin Nutr (2012) 0.91
Myeloperoxidase modulates lung epithelial responses to pro-inflammatory agents. Eur Respir J (2007) 0.90
Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J (2004) 0.88
Patient-clinician communication about end-of-life care for Dutch and US patients with COPD. Eur Respir J (2011) 0.88
Identification of microorganisms based on headspace analysis of volatile organic compounds by gas chromatography-mass spectrometry. J Breath Res (2014) 0.87
Infections with mimivirus in patients with chronic obstructive pulmonary disease. Respir Med (2012) 0.86
MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer (2003) 0.84
Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. Heart (2009) 0.84
ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr (2009) 0.83
Glucose metabolism in chronic lung disease. Clin Nutr (2002) 0.82
Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr (2004) 0.81
Fatigued muscles in COPD but no finishing line in sight. Eur Respir J (2008) 0.81
Regulation of skeletal muscle oxidative phenotype by classical NF-κB signalling. Biochim Biophys Acta (2013) 0.81
Uncoupling protein-3 content is decreased in peripheral skeletal muscle of patients with COPD. Eur Respir J (2003) 0.81
Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release. Thorax (2006) 0.80
Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Neth J Med (2012) 0.80
Glutathione and glutamate levels in the diaphragm of patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 0.80
TNF-α-induced NF-κB activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1α. Endocrinology (2015) 0.79
Hypoxia, nitrogen balance and body weight. Eur Respir J (2002) 0.77
[Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial]. Rev Port Pneumol (2006) 0.77
Association between the IL6-174G/C SNP and maximally attained lung function. Thorax (2010) 0.77
[Cognitive impairment in patients with COPD: a review]. Tijdschr Gerontol Geriatr (2014) 0.76
COPD: from an organ- to a disease-oriented approach. COPD (2008) 0.76
Introduction: systemic effects in chronic obstructive pulmonary disease. Eur Respir J Suppl (2003) 0.76
Eat well to get well. Thorax (2003) 0.75
Body composition in COPD; stepping back or moving forward? Respir Med (2009) 0.75
Activation of alternative NF-κB signaling during recovery of disuse-induced loss of muscle oxidative phenotype. Am J Physiol Endocrinol Metab (2014) 0.75
Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands. Arch Gynecol Obstet (2013) 0.75
[The last breath. The decision of whether or not to ventilate patients with severe chronic obstructive pulmonary disease]. Ned Tijdschr Geneeskd (2002) 0.75
Inflammation: friend or foe of muscle remodelling in COPD? Eur Respir J (2007) 0.75
[Two sisters with lung emphysema]. Ned Tijdschr Geneeskd (2016) 0.75
COPD: moving beyond physiological reductionism. COPD (2011) 0.75
Serum LDH and exercise capacity in COPD. Thorax (2008) 0.75
Nutritional rehabilitation: from pulmonary cachexia to sarcoPD. Eur Respir J (2009) 0.75
Pulmonary rehabilitation and integrated care. Chron Respir Dis (2005) 0.75